Genomics-based diagnostics and research firm MedGenome has raised $30 million (Rs 192 crore) in a Series C round led by existing investor Sequoia Capital and Sofina SA.

The round also saw the participation of existing investor Zodius Capital. Apart from them Infosys co-founder and former CEO Kris Gopalakrishnan and former Cognizant CEO Lakshmi Narayanan, too contributed to the round in their individual capacities.The latest round will help

The latest round will help the firm to accelerate development of the company’s affordable diagnostics tests and expand the market penetration by increasing customer awareness on the importance of genetic tests. Additionally, the funding will also be used to broaden biomarker discovery programs.

Commenting on the development, Sam Santhosh, Founder, and Chairman of MedGenome said, “Precision medicine is the ultimate goal of clinicians and patients alike which can be enabled through extensive biomarker discovery. We have established leadership in genetic diagnostics for inherited diseases in India. We will now expand DNA based testing to cover infectious diseases like tuberculosis.”

The investors see this partnership as an exciting opportunity in the development of precision medicine. “We are excited to continue this partnership that will strengthen its proposition to consumers and doctors in these markets,” Abhay Pandey, Managing Director, Sequoia Capital India Advisors.

Founded in 2013, MedGenome’s approach is two fold — on the one hand, it provides a range of genetic diagnostic tests in India, including prenatal, pediatric inherited disorders, and oncology testing. On the other hand, its lab in Silicon Valley offers sequencing platforms, bioinformatics, computing, and big data analytics.

Till date, the Bengaluru-based startup has raised a total of $54 million. MedGenome currently has more than 360 employees across its headquarters in Foster City, California and its offices/labs in Bangalore, Delhi, and Singapore.

Post a Comment

Previous Post Next Post
Like this content? Sign up for our daily newsletter to get latest updates.